SPY334.19+5.46 1.66%
DIA275.90+4.20 1.55%
IXIC11,117.53+203.96 1.87%

AIkido Pharma Sponsors Survival Study Of University Of Kentucky Anticancer Drug G4-1 In Exchange For Exclusive Option To License

NEW YORK, Aug. 18, 2020 /PRNewswire/ --AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today announced that it will provide funding for a 30-day survival study in mice in

Benzinga · 08/18/2020 13:06

NEW YORK, Aug. 18, 2020 /PRNewswire/ --AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today announced that it will provide funding for a 30-day survival study in mice in collaboration with University of Kentucky related to the anticancer drug designated G4-1, a novel proteasome inhibitor. In exchange, Aikido has been granted an exclusive option to license the drug ("Option") pending the results of the study.